Central nervous system effects of hypothalamic peptides

Area of Science:

• Neuropharmacology
• Endocrinology

Background:

• Thyroid-releasing factor (TRF) and somatostatin are peptide hormones with diverse physiological roles.
• Understanding their effects on central nervous system (CNS) drug toxicity is crucial for therapeutic applications.

Purpose of the Study:

• To investigate the comparative effects of TRF and somatostatin on the lethality of pentobarbital (PB) and strychnine.
• To explore the potential CNS activity of TRF and somatostatin.

Main Methods:

• Intravenous administration of TRF (1 mg/kg) and somatostatin (1 mg/kg) in rats.
• Assessment of LD50 (lethal dose for 50% of subjects) for pentobarbital and strychnine.
• Observation of mortality rates following administration of lethal drug doses.

Main Results:

• TRF (1 mg/kg) increased pentobarbital LD50 by 25% and abolished mortality post-lethal PB dose.
• Somatostatin (1 mg/kg) reduced pentobarbital LD50 by 30%.
• TRF decreased strychnine LD50 by 28%, while somatostatin increased it by 21% and reduced seizure duration.

Conclusions:

• TRF exhibits neuroprotective effects against pentobarbital and proconvulsant effects against strychnine.
• Somatostatin demonstrates CNS depressant effects, increasing pentobarbital lethality and reducing strychnine toxicity.
• Both TRF and somatostatin appear to exert their effects via CNS mechanisms.